Get the Stockscreener App
0.00
100.00%
-1.26
After Hours:
1.00
1.00
+
Sonnet Biotherapeutics Holdings Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
See More
Previous Close:
$1.26
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$8.60M
Revenue:
$129.20K
Net Income/Loss:
$-7.44M
P/E Ratio:
0.00
EPS:
-11.19
Net Cash Flow:
$-8.62M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$3.921
52-Week Range:
$0.00
$19.30
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
Name
Sonnet Biotherapeutics Holdings Inc
Sector
Industry
Phone
609-375-2227
Address
100 OVERLOOK CENTER, PRINCETON, NJ
Compare SONN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
0.00 | 8.60M | 129.20K | -7.44M | -8.62M | -11.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Latest News
Officer Kenney Acquires 233,374 Of Sonnet BioTherapeutics Holdings Inc [SONN] - TradingView
Hyperliquid Strategies Moves $411M in HYPE to Hypercore - Live Bitcoin News
Sonnet BioTherapeutics Stockholders Greenlight Hyperliquid Strategies Merger Deal - Blockonomi
Sonnet’s $1B Hype Treasury Signals Ambitious Digital Asset Expansion After Merger Approval - Crypto Economy
Sonnet BioTherapeutics Merges with Hyperliquid Strategies - TipRanks
Is Sonnet BioTherapeutics Holdings Inc. stock attractive for hedge fundsWeekly Trend Summary & Real-Time Buy Zone Alerts - Newser
Sonnet BioTherapeutics Holdings, Inc. (SONN) Stock: Merges Into Hyperliquid Era with Nasdaq Debut as PURR - parameter.io
Sonnet BioTherapeutics Enters a New Frontier with a $1 Billion HYPE Digital Asset Treasury - OneSafe
Sonnet BioTherapeutics shareholders approve proposed business merger with Hyperliquid Strategies Inc. - Bitget
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination - GlobeNewswire
Biotech Trio Gets Hammered On Heavy Trading - Finimize
Sonnet BioTherapeutics Approves Merger with Hyperliquid and Rorschach - MSN
Sonnet BioTherapeutics Holdings, Inc. (SONN) Stock: Shareholders Approve Hyperliquid Merger, Setting Stage for $1B HYPE Treasury - CoinCentral
Revolutionary Shift: How Sonnet BioTherapeutics Became a $305M Digital Asset Treasury Powerhouse - CryptoRank
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Sonnet shareholders approve Hyperliquid merger to launch HYPE-focused crypto treasury - Crypto Briefing
Stockholders Approve Sonnet–Hyperliquid Merger - citybiz
Sonnet shareholders approve merger for potential $1 billion HYPE crypto treasury - theblock.co
Sonnet BioTherapeutics (SONN) Stockholders Approve Business Comb - GuruFocus
Sonnet Biotherapeutics Holdings announces stockholder approval of proposed business combination with Hyperliquid Strategies - marketscreener.com
Sonnet BioTherapeutics shareholders approve business combination - Investing.com
Sonnet BioTherapeutics shareholders approve business combination By Investing.com - Investing.com Australia
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Business Combination - TradingView
Sonnet BioTherapeutics Stockholders Approve Business Combination with Hyperliquid Strategies Inc and Rorschach I LLC - Quiver Quantitative
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder - GlobeNewswire
Sonnet BioTherapeutics (NASDAQ: SONN) gets stockholder OK for Hyperliquid Strategies business combination - Stock Titan
Is Sonnet BioTherapeutics Holdings Inc. stock attractive for passive investorsJuly 2025 Rallies & Stepwise Entry/Exit Trade Alerts - Newser
Lowenstein Represents Sonnet BioTherapeutics in Closing of Business Combination with Hyperliquid Strategies - Lowenstein Sandler LLP
Sonnet BioTherapeutics (SONN) Stock Analysis Report | Financials & Insights - Benzinga
Sonnet BioTherapeutics Holdings, Inc.(NasdaqCM:SONN) dropped from NASDAQ Composite Index - marketscreener.com
What drives Sonnet BioTherapeutics Holdings Inc stock priceTrading Psychology Tips & Start Learning With Our Courses - earlytimes.in
Can Sonnet BioTherapeutics Holdings Inc. stock maintain growth trajectoryMarket Risk Summary & Breakout Confirmation Trade Signals - BỘ NỘI VỤ
What analysts say about Sonnet BioTherapeutics Holdings Inc stock - earlytimes.in
Sonnet BioTherapeutics (NASDAQ:SONN) Shares Up 3.2% – Should You Buy? - Defense World
Regression analysis insights on Sonnet BioTherapeutics Holdings Inc. performanceMarket Sentiment Report & AI Based Trade Execution Alerts - newser.com
Why Sonnet BioTherapeutics Holdings Inc. stock could benefit from AI revolution2025 Market Outlook & Weekly High Conviction Ideas - newser.com
Published on: 2025-11-20 06:58:46 - newser.com
Is Sonnet BioTherapeutics Holdings Inc. stock a buy on dipsSell Signal & Precise Swing Trade Entry Alerts - newser.com
Can Sonnet BioTherapeutics Holdings Inc. stock rebound after recent weaknessJuly 2025 EndofMonth & Long-Term Safe Investment Ideas - newser.com
Is Sonnet BioTherapeutics Holdings Inc. stock a good choice for value investors2025 Buyback Activity & Stepwise Entry and Exit Trade Signals - newser.com
Can Sonnet BioTherapeutics Holdings Inc. stock outperform in 2025 bull market - newser.com
What high frequency data says about Sonnet BioTherapeutics Holdings Inc. - newser.com
Using data models to predict Sonnet BioTherapeutics Holdings Inc. stock movementWeekly Investment Summary & Low Risk High Reward Trade Ideas - newser.com
Sentiment analysis tools applied to Sonnet BioTherapeutics Holdings Inc.Portfolio Gains Summary & Free Safe Entry Trade Signal Reports - newser.com
Is Sonnet BioTherapeutics Holdings Inc. meeting your algorithmic filter criteriaJuly 2025 Technicals & Real-Time Volume Triggers - newser.com
How risky is Sonnet BioTherapeutics Holdings Inc. stock nowQuarterly Earnings Summary & Reliable Price Breakout Signals - newser.com
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know - The Motley Fool
Will Sonnet BioTherapeutics Holdings Inc. stock reach Wall Street targets2025 Valuation Update & Fast Exit and Entry Trade Guides - newser.com
What momentum shifts mean for Sonnet BioTherapeutics Holdings Inc.Market Trend Report & Fast Exit Strategy with Risk Control - newser.com
Sonnet BioTherapeutics Holdings Inc. (SONN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Sonnet BioTherapeutics Holdings Inc. outperform the marketJuly 2025 EndofMonth & Safe Capital Growth Tips - newser.com
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):